BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
10.75
-0.13 (-1.19%)
At close: May 30, 2025, 4:00 PM
10.89
+0.14 (1.30%)
After-hours: May 30, 2025, 7:25 PM EDT
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $145.53M in the quarter ending March 31, 2025, with 56.89% growth. This brings the company's revenue in the last twelve months to $503.49M, up 41.67% year-over-year. In the year 2024, BioCryst Pharmaceuticals had annual revenue of $450.71M with 36.00% growth.
Revenue (ttm)
$503.49M
Revenue Growth
+41.67%
P/S Ratio
4.43
Revenue / Employee
$868,078
Employees
580
Market Cap
2.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BCRX News
- 21 hours ago - BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages - GlobeNewsWire
- 3 days ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) - GlobeNewsWire
- 16 days ago - BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years - GlobeNewsWire
- 25 days ago - BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors - Benzinga
- 25 days ago - BioCryst: Strong Opportunity For A Double With A Proven Therapy - Seeking Alpha
- 25 days ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire